IMA402 — Initial data
2H 2026
RP2D determination and Phase 1 clinical data update with focus on melanoma and gynecologic cancers treated with IMA402 monotherapy and combination with immune checkpoint inhibitor planned for 2H 2026Source filing
IMTX biotech catalysts & pipeline
IMMATICS NV · Data as of 2026-10-25
Upcoming catalysts
anzutresgene autoleucel (anzu-cel, IMA203) — Topline data
H1 2027
The Company expects to disclose topline data from the final PFS analysis in the first half of 2027, followed by a BLA submission in 2027.Source filing
anzutresgene autoleucel (anzu-cel, IMA203) — NDA/BLA submission
1H 2027
Findings reinforce the continued effectiveness of anzu-cel to treat advanced melanoma; Phase 3 SUPRAME trial remains on track as it advances toward BLA submission in 1H 2027Source filing
IMA401 — Clinical data readout
2027
First data from the IMA401/IMA402 combination cohort are expected in 2027.Source filing